Stockscreener 앱 받기
2.335
11.55%
-0.305
시간 외 거래:
2.34
0.005
+0.21%
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Lexeo stock hits 52-week low at $2.31 amid sharp annual decline - Investing.com India
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Raised by Bank of New York Mellon Corp - Defense World
What is Chardan Capital’s Estimate for LXEO FY2025 Earnings? - Defense World
Q1 EPS Estimate for Lexeo Therapeutics Increased by Analyst - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $18.00 at Leerink Partners - MarketBeat
HC Wainwright Reaffirms Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
What is Leerink Partnrs’ Forecast for LXEO FY2025 Earnings? - Defense World
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? - MSN
Analysts Offer Predictions for LXEO Q1 Earnings - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $20.00 at Royal Bank of Canada - Defense World
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
H.C. Wainwright maintains Buy on Lexeo stock, $23 target By Investing.com - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's - Asianet Newsable
Pharma Frenzy: Volatility Ignites Biotech Sector - Sharewise
Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - MSN
RBC Cuts Price Target on Lexeo Therapeutics to $20 From $24, Keeps Outperform, Speculative Risk - MarketScreener
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Cut to $18.00 by Analysts at Leerink Partners - Defense World
Lexeo Therapeutics Advances Genetic Medicine Initiatives - TipRanks
10 Small Firms Kick Off Monday with Strong Gains - Insider Monkey
Leerink cuts Lexeo Therapeutics price target to $18, maintains Outperform By Investing.com - Investing.com Canada
Lexeo Therapeutics stock soars 40% on positive trial data By Investing.com - Investing.com South Africa
Lexeo Therapeutics stock soars 40% on positive trial data - Investing.com India
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - MarketScreener
SEC Form 424B5 filed by Lexeo Therapeutics Inc. - Quantisnow
Lexeo Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $75 MillionSEC Filing - Marketscreener.com
Lexeo Therapeutics, Inc. (LXEO) reports earnings - Quartz
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - The Manila Times
Insider Stock Buyers At Lexeo Therapeutics Recouped Some Losses This Week - simplywall.st
Lexeo Therapeutics (NASDAQ:LXEO) & Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey - Defense World
LEXEO THERAPEUTICS Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Purchases 4,127 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Lexeo Therapeutics (LXEO) to Release Quarterly Earnings on Monday - Defense World
Lexeo stock hits 52-week low at $4.23 amid market challenges - MSN
Lexeo stock plunges to 52-week low at $3.42 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock plunges to 52-week low at $3.42 amid market challenges - Investing.com India
Lexeo Therapeutics chief medical officer sells $10,410 in stock By Investing.com - Investing.com South Africa
Lexeo Therapeutics CEO sells $19,090 in stock By Investing.com - Investing.com Nigeria
Top Executives at Lexeo Therapeutics Cash In on Stock Sales! - TipRanks
Lexeo Therapeutics chief development officer sells shares worth $6,557 - Investing.com
Lexeo Therapeutics CEO sells $19,090 in stock - Investing.com India
Lexeo Therapeutics chief medical officer sells $10,410 in stock - Investing.com India
Lexeo Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Lexeo Therapeutics CMO Sells Shares to Cover Tax Obligations - TradingView
3.01%
자본화:
|
볼륨(24시간):